LIMITED OFFER
Save 50% on book bundles
Immediately download your ebook while waiting for your print delivery. No promo code is needed.
Save up to 30% on Elsevier print and eBooks with free shipping. No promo code needed.
Save up to 30% on print and eBooks.
Nanotechnology-based therapeutics, operating at scales of billionths of a metre, have great potential for future expansion in altering the scale and methods of drug delivery. The… Read more
LIMITED OFFER
Immediately download your ebook while waiting for your print delivery. No promo code is needed.
List of figures
List of tables
Foreword
Chapter 1: Nanoparticulate systems as drug carriers: the need
Abstract:
1.1 Introduction: nanoparticles for drug delivery
1.2 Need: solubility, bioavailability, targeting and more
1.3 Specific nanoparticulate strategies for overcoming solubility and bioavailability limitations
Chapter 2: Nanoparticles as drug carriers
Abstract:
2.1 Nanoparticles as drug carriers: the scope
2.2 Nanoparticles as drug delivery carriers
2.3 Application areas for nanoparticulate drug delivery systems
2.4 Routes of administration of nanoparticulate drug delivery systems
2.5 Conclusion
Chapter 3: Characterization techniques for nanoparticulate carriers
Abstract:
3.1 Need and challenges for characterization techniques of nanoparticulate drug carriers
3.2 Measuring the size of nanoparticles
3.3 Zeta potential measurement [1, 4]
3.4 Characterizing the morphology of the nanoparticles
3.5 Assessing the sterility and detecting mycoplasma or microbial contamination of nanoparticles [46, 47]
3.6 Toxicity evaluation of nanoparticles
3.7 Evaluating immunological potential of nanoparticles
Chapter 4: Nanotoxicology: evaluating toxicity potential of drug-nanoparticles
Abstract:
4.1 Nanotoxicology: need towards developing safe and sustainable drug delivery systems
4.2 In vitro assays for assessing toxicity of nanoparticles
4.3 In-vivo assays for assessing toxicity of nanoparticles
4.4 Genotoxicity evaluation
Chapter 5: Regulatory aspects of nanoparticulate drug delivery systems
Abstract:
5.1 Nanoparticulate drug carriers: the regulatory facet
5.2 Issues associated with regulating nano-drug delivery systems
5.3 Current approaches for regulating pharmaceutical nanocarriers
Chapter 6: Clinical trials industrial aspects
Abstract:
6.1 Clinical trials of nanoparticulate drug delivery systems: successes and failures
6.2 Case studies: cancer
6.3 Case studies: other diseases
6.4 Nanoparticulate drug delivery: an industrial outlook
Chapter 7: Case studies: nano-systems in the market
Abstract:
7.1 Case studies: performance and market approval
7.2 Are nano or conventional drug delivery systems a better choice? – a market overview
7.3 Future perspectives on nanoparticulate drug carriers
Index
VP
PD
RJ